Ignite Creation Date:
2024-05-06 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06221670
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-24
First Post:
2024-01-14
Brief Title:
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations EGFR or ALK
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Organization Data
Organization:
Tianjin Medical University Cancer Institute and Hospital
Class:
OTHER
Study ID:
NSCLC-Toripalimab-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None